Mixed Connective Tissue Disease (MCTD)
This patient most likely has Mixed Connective Tissue Disease (MCTD), based on the constellation of elevated anti-U1 ribonucleoprotein antibodies, Raynaud's phenomenon, sicca symptoms (dry eyes/mouth), hand swelling with difficulty making fists, high-titer ANA (1:640), and pleuritic chest pain.
Diagnostic Reasoning
The clinical presentation creates a highly specific pattern for MCTD:
Key Diagnostic Features Present
Anti-U1 RNP antibodies (elevated): This is the hallmark autoantibody of MCTD and is found across the spectrum of rheumatic diseases including undifferentiated connective tissue disease, scleroderma, and SLE 1, 2, 3
Raynaud's phenomenon: Affects most patients with MCTD and frequently represents the initial manifestation. The association between Raynaud's and anti-U1-RNP is characteristic across rheumatic diseases 1, 2
High-titer ANA (1:640): ANA titers >1:160 strongly suggest connective tissue disease rather than idiopathic pulmonary fibrosis or other conditions 4. The presence of high titers with specific anti-U1 RNP positivity points toward MCTD 3
Hand swelling ("puffy hands") with difficulty making fists: This represents the characteristic sclerodactyly and hand edema seen in MCTD, which shares features with systemic sclerosis 1, 2
Sicca symptoms (dry eyes and mouth): While anti-SSA and anti-SSB are negative, sicca symptoms are common in MCTD. Many patients develop these symptoms but tend to be seronegative for Sjögren's-specific antibodies 5, 6, 5
Pleuritic chest pain (worse when lying down): This suggests serositis (pleuritis or pericarditis), which is a recognized feature of connective tissue diseases. The positional nature (worse supine) is characteristic of pericarditis 7
Why Not Other Diagnoses
Systemic Sclerosis (Scleroderma): While this patient has Raynaud's and hand swelling, the negative anti-Scl-70 (topoisomerase) and anti-centromere antibodies, combined with positive anti-U1 RNP, favor MCTD over isolated scleroderma 2, 8
Sjögren's Syndrome: The negative anti-SSA and anti-SSB antibodies make primary Sjögren's unlikely, despite sicca symptoms 5, 6
SLE: While SLE can present with high ANA and pleuritis, anti-U1 RNP antibodies in high titers with this specific clinical constellation (especially Raynaud's and hand swelling) are more characteristic of MCTD 3
Clinical Significance and Prognosis
MCTD represents a systemic vasculopathy characterized by intimal fibrosis and blood vessel obliteration that can lead to visceral involvement, particularly pulmonary hypertension 1. The chest pain warrants evaluation for:
- Pericarditis/pleuritis: Most likely given positional nature
- Early pulmonary hypertension: A serious complication requiring echocardiographic screening
- Coronary vasospasm: Can occur with severe Raynaud's
Immediate Next Steps
Echocardiography: To assess for pericardial effusion, pericarditis, and estimate pulmonary artery pressures 9
Nailfold capillaroscopy: Represents a valuable tool to identify patients at risk for MCTD and assess vascular damage. Abnormal patterns (enlarged capillaries, hemorrhages, avascular areas) support secondary Raynaud's and predict disease progression 1, 2
Pulmonary function tests: To establish baseline and screen for interstitial lung disease
Rheumatology referral: For confirmation of diagnosis and initiation of disease-modifying therapy
Important Caveats
- The term "MCTD" should be distinguished from "overlap syndrome" - MCTD specifically requires anti-U1 RNP positivity 3
- Trophic abnormalities and digital ulcers are frequently observed in MCTD, requiring aggressive vascular protection 2
- Some patients initially diagnosed with MCTD may evolve into more defined connective tissue diseases over time, requiring ongoing monitoring 4
The combination of anti-U1 RNP positivity with this clinical presentation makes MCTD the most likely diagnosis, requiring prompt rheumatologic evaluation and treatment to prevent progression of vascular complications 1, 2.